Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Nestin-driven oncolytic viruses show effectiveness in glioblastoma models

Nestin-driven oncolytic viruses show effectiveness in glioblastoma models

Two proteins bind together to ignite and sustain malignant brain tumors

Two proteins bind together to ignite and sustain malignant brain tumors

Brain tumour discovery offers drug treatment hope

Brain tumour discovery offers drug treatment hope

Scientists uncover vast new gene regulatory network linked with cancer

Scientists uncover vast new gene regulatory network linked with cancer

Nature publishes Sangamo's gene correction strategy for A1AT deficiency

Nature publishes Sangamo's gene correction strategy for A1AT deficiency

Scientisits uncover evidence of powerful new cancer genetic networks

Scientisits uncover evidence of powerful new cancer genetic networks

UCLA's screening system can target stem cells responsible for glioblastoma

UCLA's screening system can target stem cells responsible for glioblastoma

First patient treated with MagForce's NanoTherm therapy for recurrent glioblastoma

First patient treated with MagForce's NanoTherm therapy for recurrent glioblastoma

ImmunoCellular receives U.S. patent allowance for ICT-107 to treat GBM

ImmunoCellular receives U.S. patent allowance for ICT-107 to treat GBM

Sangamo's SB-509 fails to meet key endpoints in Phase 2b study for diabetic neuropathy

Sangamo's SB-509 fails to meet key endpoints in Phase 2b study for diabetic neuropathy

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors

Enrollment complete in Rexahn's Archexin Phase II trial for metastatic pancreatic cancer

Enrollment complete in Rexahn's Archexin Phase II trial for metastatic pancreatic cancer

YM BioSciences begins enrollment in CYT387 Phase II trial for myelofibrosis

YM BioSciences begins enrollment in CYT387 Phase II trial for myelofibrosis

Data from YM BioSciences' nimotuzumab clinical trials to be reported at ECCO-ESMO 2011

Data from YM BioSciences' nimotuzumab clinical trials to be reported at ECCO-ESMO 2011

YM BioSciences total revenue decreases to $1.5 million for fiscal 2011

YM BioSciences total revenue decreases to $1.5 million for fiscal 2011

New assay simultaneously visualize gene number, protein expression in individual cells

New assay simultaneously visualize gene number, protein expression in individual cells

USPTO issues patent for Lixte's LB-100 to treat cancer

USPTO issues patent for Lixte's LB-100 to treat cancer

ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM

ImmunoCellular announces updated long-term data from ICT-107 Phase I trial on GBM

Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer

Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.